EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (Amex:AIS) announced receipt of Notice of Allowance from the United States Patent & Trademark Office (USPTO) covering semi-solid pharmaceutical compositions used in its Advanced Transdermal Delivery (ATD™) technology. The USPTO has stated that it intends to grant patent protection which covers hormonal and non-hormonal formulations developed by Antares Pharma. The patent is expected to issue mid-year and will remain in force until 2021.
